New preclinical findings  with vidofludimus.
D000284:Administration, Oral; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D001327:Autoimmune Diseases / Q000188:drug therapy*; D001713:Biphenyl Compounds / Q000008:administration & dosage / Q000627:therapeutic use*; D003998:Dicarboxylic Acids / Q000008:administration & dosage / Q000627:therapeutic use*; D004353:Drug Evaluation, Preclinical; D006801:Humans
D000893:Anti-Inflammatory Agents; D001713:Biphenyl Compounds; D003998:Dicarboxylic Acids; C553728:vidofludimus